Mineralys Therapeutics (MLYS) Institutional Ownership
13F filers reported holding 40.4% of Mineralys Therapeutics (MLYS) shares as of Sep 30, 2026, across 116 filers.
- Held by 13F filers
- 40.4%
- Sep 30, 2026
- 13F filers
- 116
- quarter ended Sep 30, 2026
- 13F value
- $900.0M
- 35.8M shares
- Quarter's fund flow
- Mild accumulation
- 21 new · 11 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | COATS LONNEL | director | Acquired · Grant / award | 12,400 | — | ↗ |
| Oct 19, 2026 | COATS LONNEL | director | Acquired · Grant / award | 16,600Stock Option | — | ↗ |
| Oct 19, 2026 | Peterson Kristine | director | Acquired · Grant / award | 12,400 | — | ↗ |
| Oct 19, 2026 | Peterson Kristine | director | Acquired · Grant / award | 16,600Stock Option | — | ↗ |
| Sep 30, 2026 | Congleton Jon | Chief Executive Officer | Disposed · Open-market sale | 75,000 | $25.46 | ↗ |
| Sep 22, 2026 | Slingsby Brian Taylor | director | Disposed · Open-market sale | 104,320 | $28.81 | ↗ |
| Sep 21, 2026 | Warren Eric | Chief Commercial Officer | Acquired · Option exercise | 7,438 | $13.24 | ↗ |
| Sep 21, 2026 | Warren Eric | Chief Commercial Officer | Disposed · Open-market sale | 7,438 | $28.12 | ↗ |
| Sep 21, 2026 | Warren Eric | Chief Commercial Officer | Disposed · Option exercise | 7,438Stock Option | — | ↗ |
| Sep 15, 2026 | Karydas Daphne | director | Acquired · Option exercise | 3,000 | $12.02 | ↗ |
| Sep 15, 2026 | Karydas Daphne | director | Disposed · Open-market sale | 3,000 | $28.58 | ↗ |
| Sep 15, 2026 | Karydas Daphne | director | Disposed · Option exercise | 3,000Stock Option | — | ↗ |
| Aug 21, 2026 | Warren Eric | Chief Commercial Officer | Acquired · Option exercise | 7,437 | $13.24 | ↗ |
| Aug 21, 2026 | Warren Eric | Chief Commercial Officer | Disposed · Open-market sale | 7,437 | $25.98 | ↗ |
| Aug 21, 2026 | Warren Eric | Chief Commercial Officer | Disposed · Option exercise | 7,437Stock Option | — | ↗ |
| Aug 10, 2026 | Ferguson James J. III | Chief Medical Officer | Acquired · Grant / award | 102,400 | — | ↗ |
| Aug 10, 2026 | Ferguson James J. III | Chief Medical Officer | Acquired · Grant / award | 135,000Stock Option | — | ↗ |
| Aug 10, 2026 | Rodman David Malcom | Chief Medical Officer | Acquired · Option exercise | 2,170 | $16.00 | ↗ |
| Aug 10, 2026 | Rodman David Malcom | Chief Medical Officer | Disposed · Open-market sale | 2,170 | $27.09 | ↗ |
| Aug 10, 2026 | Rodman David Malcom | Chief Medical Officer | Disposed · Option exercise | 2,170Stock Option | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Mineralys Therapeutics do institutions hold?
13F filers reported holding 40.4% of Mineralys Therapeutics' shares as of Sep 30, 2026, across 116 filers.
How many 13F filers hold Mineralys Therapeutics?
Mineralys Therapeutics was held by 116 13F filers as of Sep 30, 2026.
Not investment advice.

